Baxter International Inc (BAX) is Upgraded by Piper Jaffray to Overweight

Baxter International Inc (BAX) was Upgraded by Piper Jaffray to ” Overweight”. Earlier the firm had a rating of “Neutral ” on the company shares. Piper Jaffray advised their investors in a research report released on Apr 14, 2016.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Feb 3, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 40 from a previous price target of $37 .

On the company’s financial health, Baxter International Inc reported $0.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.11 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.32. The company had revenue of $2603.00 million for the quarter, compared to analysts expectations of $2544.60 million. The company’s revenue was down -6.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.34 EPS.

Baxter International Inc opened for trading at $41.96 and hit $42.225 on the upside on Monday, eventually ending the session at $41.94, with a gain of 0.24% or 0.1 points. The heightened volatility saw the trading volume jump to 35,29,950 shares. Company has a market cap of $22,978 M.

In a different news, on Apr 6, 2016, John D Forsyth (director) sold 1,887 shares at $41.75 per share price. According to the SEC, on Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price. On Mar 15, 2016, James R Iii Gavin (director) sold 5,660 shares at $40.34 per share price, according to the Form-4 filing with the securities and exchange commission.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Baxter International Inc

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.